Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02116894 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer
A Phase 1 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT02116894 is a Phase 1 study that has completed, run by Duke University. The registered enrollment target is 11 participants.
The verdict
NCT02116894, a Phase 1 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
The primary objective of this open-label phase Ib trial is to determine the maximum tolerated dose and the recommended phase II dose for the combination of PF-03446962 plus regorafenib in patients with metastatic colorectal cancer. The secondary objectives are to describe the safety and tolerablility, and to describe the clinical activity of PF-03446962 plus regorafenib in terms of response rate and progression free survival
Interventions
- DRUG Regorafenib
- BIOLOGICAL PF-03446962
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2014-08 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02116894
The ClinicalTrials.gov registry entry for NCT02116894 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Regorafenib is the first listed.
NCT02116894 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02116894 about?
NCT02116894 is a clinical study titled "Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer". The primary objective of this open-label phase Ib trial is to determine the maximum tolerated dose and the recommended phase II dose for the combination of PF-03446962 plus regorafenib in patients with metastatic colorectal cancer. The secondary objectives are to describe the safety and tolerablilit...
What is the current status of trial NCT02116894?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2014-08. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02116894?
The interventions under investigation include: Regorafenib (DRUG), PF-03446962 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02116894?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.